Tissue dihydrotestosterone and 5α-reductase (Δ4-3-ketosteroid-5α-oxidoreductase) levels have been measured in prostates of patients with cancer and benign prostatic hypertrophy; significant decreases in average values for both of these biochemical parameters were noted in prostate cancer compared to benign prostatic hypertrophy, although individual values overlapped in both groups. Prostate cancer tissue dihydrotestosterone levels appeared to correlate better than did either histological tumor grading or 5α-reductase with the ultimate clinical response to antiandrogen therapy. These results suggest that assay of tissue dihydrotestosterone levels in prostate cancer should be further explored as a possible marker for tumor differentiation.

1

Presented at the John E. Fogarty International Center Conference on Hormones and Cancer, March 29 to 31, 1978, Bethesda, Md. Supported by Grant 5 R26 CA18003-02, awarded by the National Cancer Institute, Department of Health, Education and Welfare.

This content is only available via PDF.
©1978 American Association for Cancer Research.
1978
Cancer Research, Inc.